CC
SRPT icon

Casdin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Casdin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-990,097
Closed -$16.9M – 37
2025
Q2 		$16.9M Buy
990,097
+89,314
+10% +$3.81M 1.54% 14
2025
Q1 		$57.5M Sell
900,783
-172,717
-16% -$18.2M 4.7% 6
2024
Q4 		$131M Hold
1,073,500
– – 8.69% 4
2024
Q3 		$134M Hold
1,073,500
– – 8.94% 5
2024
Q2 		$170M Buy
1,073,500
+4,500
+0.4% +$578K 12.95% 3
2024
Q1 		$138M Buy
1,069,000
+62,500
+6% +$7.66M 10.29% 4
2023
Q4 		$97.1M Sell
1,006,500
-3,830
-0.4% -$367K 9.53% 3
2023
Q3 		$122M Sell
1,010,330
-4,670
-0.5% -$528K 13.55% 1
2023
Q2 		$116M Sell
1,015,000
-145,000
-13% -$18.7M 10.16% 2
2023
Q1 		$160M Sell
1,160,000
-155,000
-12% -$20.1M 13.17% 2
2022
Q4 		$170M Buy
1,315,000
+90,000
+7% +$10.4M 13.2% 1
2022
Q3 		$135M Buy
1,225,000
+575,000
+88% +$58M 8.9% 3
2022
Q2 		$48.7M Sell
650,000
-150,000
-19% -$11M 4.12% 9
2022
Q1 		$62.5M Sell
800,000
-550,000
-41% -$42.1M 2.8% 14
2021
Q4 		$122M Buy
1,350,000
+250,000
+23% +$21.4M 3.43% 12
2021
Q3 		$102M Buy
1,100,000
+215,000
+24% +$16.6M 2.53% 13
2021
Q2 		$68.8M Buy
885,000
+335,000
+61% +$25.4M 1.75% 20
2021
Q1 		$41M Buy
550,000
+20,000
+4% +$1.85M 1.22% 23
2020
Q4 		$90.4M Hold
530,000
– – 2.68% 13
2020
Q3 		$74.4M Hold
530,000
– – 3.33% 9
2020
Q2 		$85M Sell
530,000
-140,000
-21% -$19.1M 5.03% 4
2020
Q1 		$65.5M Hold
670,000
– – 6.96% 2
2019
Q4 		$86.5M Sell
670,000
-210,000
-24% -$21.2M 7.95% 1
2019
Q3 		$66.3M Buy
880,000
+545,000
+163% +$64.4M 6.86% 5
2019
Q2 		$50.9M Buy
335,000
+30,000
+10% +$3.65M 4.76% 8
2019
Q1 		$36.4M Buy
305,000
+155,000
+103% +$19.9M 3.99% 13
2018
Q4 		$16.4M Buy
150,000
+110,000
+275% +$13.8M 2.8% 16
2018
Q3 		$6.46M Buy
+40,000
New +$5.47M 0.79% 29

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Casdin Capital's SRPT Position: Q3 2025 in Review

Casdin Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 990,097 shares — an estimated $16.9M sold.

Casdin Capital first reported a position in SRPT in Q3 2018 and held it in 28 quarters. The position peaked at $170M in Q4 2022. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Casdin Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Casdin Capital sold 990,097 Sarepta Therapeutics shares in Q3 2025, an estimated $16.9M.
  • Casdin Capital first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 28 quarters.
  • Casdin Capital's Sarepta Therapeutics position peaked at $170M in Q4 2022.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.